569,000 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by Eventide Asset Management LLC

Eventide Asset Management LLC purchased a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) during the 4th quarter, Holdings Channel.com reports. The fund purchased 569,000 shares of the company’s stock, valued at approximately $14,225,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC increased its stake in Olema Pharmaceuticals by 9,476.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock worth $31,000 after buying an additional 1,232 shares during the period. Torren Management LLC purchased a new stake in Olema Pharmaceuticals during the 4th quarter worth $44,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new stake in Olema Pharmaceuticals during the 4th quarter worth $88,000. Nisa Investment Advisors LLC increased its stake in Olema Pharmaceuticals by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock worth $94,000 after buying an additional 477 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Olema Pharmaceuticals by 44.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock worth $96,000 after buying an additional 1,169 shares during the period. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on OLMA. TD Cowen reaffirmed a “buy” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th. The Goldman Sachs Group dropped their price target on shares of Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating on the stock in a research note on Wednesday, March 18th. Wall Street Zen raised shares of Olema Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, April 27th. JPMorgan Chase & Co. raised their price objective on shares of Olema Pharmaceuticals from $55.00 to $58.00 and gave the stock an “overweight” rating in a report on Wednesday, March 18th. Finally, Oppenheimer reissued an “outperform” rating on shares of Olema Pharmaceuticals in a report on Monday, March 9th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Olema Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.10.

Olema Pharmaceuticals Price Performance

Shares of OLMA stock opened at $9.87 on Monday. The firm has a market cap of $862.14 million, a P/E ratio of -4.89 and a beta of 1.98. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.88 and a quick ratio of 10.88. Olema Pharmaceuticals, Inc. has a 1-year low of $3.89 and a 1-year high of $36.26. The firm has a fifty day moving average of $13.96 and a two-hundred day moving average of $20.54.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) earnings per share for the quarter, hitting the consensus estimate of ($0.52). As a group, research analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.16 earnings per share for the current fiscal year.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.